Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

The Daily Gate mobile app brings you the latest local breaking news, updates, and more. Read the Daily Gate on your mobile device just as it appears in print.

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

In 2019, the FDA approved Spravato, "a nasal spray derived from ketamine," for treating severe depression. "But that approval came with strict guardrails to ensure patient safety," added the Post ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...

Ketamine is an old anesthesia drug with psychedelic qualities, and it has been getting a lot of attention for its ability to ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

The nasal variant of ketamine, esketamine, was developed by Johnson & Johnson Pharmaceuticals under the name brand Spravato; it’s the only type of ketamine approved by the FDA for treatment ...